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OP-ED

Promoting ethical standards in globalized drug
trials through market exclusion
By Fazal Khan, Assistant Professor of Law, UGA

She was only ten years old and
suffering from a serious infectious disease
that was sweeping through West Africa,
bacterial meningitis. But for this little girl
and her family there was seemingly good
news; there exists an effective treatment
for bacterial meningitis, intravenous
antibiotics. Further, once they arrived
at the clinic in Kano, Nigeria, they saw
Western doctors in white coats offering to
provide medical treatment for free. And
yet, three days later the girl died – not
having received any proven antibiotic
therapy, but only an experimental drug
called Trovan.1
The family of the girl later claimed,
along with many others, that instead of
receiving proper medical care, they were
unwitting participants in a multinational
drug company’s experimental trial that
led to the death or serious impairment
of numerous children.2 But why would a
drug company ever do something like this?
Well, if data from the experiment helped
the drug obtain market approval, and it
became a market blockbuster, a company
would have over a billion reasons.
The potential for tremendous financial
reward generated by a newly approved
drug provides a strong incentive for drug
companies to move human subject testing
to “developing countries,” where minimal
ethical guidelines and little transparency
are the norm. The drug industry is acutely
aware that there is minimal threat of costly
civil and criminal legal sanctions for any
of their ethical violations in impoverished
countries. One study looking at drug trials
in sub-Saharan Africa found that only 16
percent of these clinical drug trials met
international ethical standards, despite 81
percent of them reporting oversight by an
ethics review board. 3

and justice. As Nobel-laureate economist
The globalization of clinical trials really
Amartya Sen has stated:
became enabled after a 1980 Food and
Even though I’m pro-globalization,
Drug Administration (FDA) ruling that
I have to say thank God for the antiallowed data from foreign trials to be
globalization movement. They’re putting
used in new drug applications (NDA).
important issues on the
Certain foreign studies used
agenda… My attitude to
to support an NDA may opt to
globalization is that one
avoid direct FDA regulation, but
has to recognize first of all
must still satisfy FDA-imposed
its inevitability, secondly its
ethical standards – either
importance as an intellectual,
the Declaration of Helsinki
social, political force, even
guidelines or regulations of the
as an economic force, but
country where the research
recognize that it can be very
was conducted, “whichever
unjust and unfair and unequal,
represents the greater
but these are matters under
protection of the individual.”4
Fazal Khan
our control.5
The Declaration of Helsinki,
an ethical code put out by the
In other words, even though
World Medical Association that governs
the process may be inevitable, we are
research involving human subjects, has
not powerless to control the actions of
thus become the de facto international
drug companies who conduct testing on
ethical standard. Therefore, in theory,
human subjects in developing nations.
under these FDA guidelines there should
What can be done to address this
not be a “race to the bottom” problem,
problem? Multinational companies are
as an underdeveloped country’s lax
notoriously difficult to regulate. By using
standards would automatically be
multiple facilities around the globe,
upgraded to Declaration of Helsinki
corporations can strategically evade state
standards. And yet, we are still seeing
power and certain national regulatory
consistent violations of ethical standards.
schemes. From an international law
Globalization of the pharmaceutical
perspective, the challenges are both
industry and clinical drug testing is
“horizontal” and “vertical” in nature, and
not necessarily a bad thing. Indeed,
the legal responses can be “hard” or “soft.”
without this process, cures for seemingly
For clinical drug trials, “horizontal”
intractable diseases like cancer or AIDS
challenges constitute problems that
might not be possible in the near future.
arise between nations trying to regulate
Further, many patients in the developing
multinational drug companies that
world might not have access to any
operate across international borders.
medical attention at all, were it not for
“Vertical” challenges are problems with
clinical drug testing. However, the real and
unethical trials that nations, more likely
potential benefits offered by globalization
developing nations with limited resources,
in the drug industry do not require us
face inside their borders. “Hard-law” is
to silently accept violations of ethical
represented by rule-based systems with
standards or the absence of accountability
binding authority on member states,

1 Joe Stephens, The Body Hunters: Exporting Human Experiments: Where Profits and Lives Hang in the Balance: Finding an Abundance of Subjects and Lack of Oversight Abroad, Big Drug

Companies Test Offshore to Speed Products to Market, WASH. POST., Dec. 17, 2000, at A1.
2 Abdullahi v. Pfizer, 2002 U.S. Dist. LEXIS 17436.
3 See David M. Kent et al., Clinical Trials in Sub-Saharan Africa and Established Standards of Care: Systematic Review of HIV, Tubercolosis, and Malaria Trials, 292 JAMA 237, 239 (2004).
4 See 21 C.F.R. Sec. 312.120(5)(c)(1)(2005).
5 Interview of Amartya Sen with David Barsamian accessed at http://www.indiatogether.org/interviews/sen.htm#part2.
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“

…The potential for tremendous financial reward generated by a
newly approved drug provides a strong incentive for drug companies
to move human subject testing to “developing countries,” where
minimal ethical guidelines and little transparency are the norm.

”

such as the system in place under the
World Trade Organization (WTO). “Softlaw” represents guidelines, practices, and
policies generated by non-governmental
organizations for voluntary self-regulation
by industry or future adoption by states.
Addressing the ethical problems
associated with globalized trials, some
scholars have advocated a “hard,
horizontal” approach, investing an
international organization such as the
World Health Organization (WHO) with
binding authority to enforce ethical
standards in clinical trials on a global basis.
The problem with this approach is one of
sovereignty and enforcement. Namely,
how would an international organization
enforce its decisions upon an unwilling
sovereign nation?
Other commentators have argued for a
“hard, vertical” approach with horizontal
effects; that is, an expansive reading of
the Alien Tort Statute (ATS) to allow U.S.
courts to enforce foreign violations of
ethical standards. However, after the U.S.
Supreme Court’s 2004 decision in Sosa v.
Alvarez-Machain, it became more difficult
for foreign plaintiffs to assert ATS claims.
Indeed, the class of Nigerian plaintiffs who
sued Pfizer in the U.S. over their Trovan
drug trials (see supra) had their case
dismissed for failure to state a cognizable
ATS claim (the court indicated that their
suit would be dismissed on forum non
conveniens grounds as well). Thus, while
the proposals discussed above advocate
for more accountability and justice in
globalized drug trials, it is unlikely that in
practice they would offer more protection
for vulnerable research populations.

A more feasible and effective strategy
would be to use “horizontal, soft-law”
measures such as increased monitoring
and reporting on globalized drug trials
that in turn could be used to enforce
existing “hard-law” drug approval
regulations vertically in lucrative markets
such as the United States, Japan, and
the European Union. The significance of
these provisions is that drugs developed
unethically could technically be excluded
from the marketplace because of the
impermissibility of the underlying clinical
trials. Thus, if the fruits of unethical
research were denied access to U.S.,
Japanese, or EU markets, it would have
the same effect as a global prohibition, as
no drug company would develop a drug
in such a manner if they knew they would
lose out on even one of these lucrative
markets.
With the increasing accessibility of
cheap internet communication, human
research subjects and concerned citizens
in developing nations can be empowered
to effectuate much of the surveillance and
monitoring activities of clinical drug trials.
For instance, WHO could maintain a multilingual website for the reporting of alleged
ethical violations. A credible report could
then prompt WHO officials to obtain a
sworn statement from the reporter, which
would then trigger an investigation into
the alleged ethical abuses. Verified reports
of ethical abuses can then be taken into
account by drug regulatory agencies when
determining whether a drug should obtain
market approval.
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